Anbio Biotechnology (NNNN) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alpha Teknova (TKNO) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 77.4% versus a loss of 86.0%. Alpha Teknova is the larger company by market cap ($480.0 million vs $145.7 million), about 3.3 times the size. Anbio Biotechnology converts more of its revenue into profit, with a net margin of 74.1% versus -42.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | TKNO |
|---|---|---|
| Share price | $3.32 | $7.63 |
| Market cap | $145.72M | $479.95M |
| 1-day change | -9.04% | -2.30% |
| YTD return | -88.96% | +100.79% |
| 1-year return | -86.02% | +77.44% |
| 5-year return | — | -63.63% |
| P/E ratio (TTM) | 22.13 | — |
| EPS (TTM) | $0.15 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.65M | $40.52M |
| Revenue growth (YoY) | +5.64% | +7.35% |
| Net income (latest FY) | $6.40M | $-17.26M |
| Gross margin | 87.24% | 33.17% |
| Operating margin | 66.70% | -41.90% |
| Net margin | 74.06% | -42.59% |
| 52-week high | $44.73 | $9.48 |
| 52-week low | $3.09 | $1.91 |
| Distance from 52-week high | -92.58% | -19.51% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +28.83% |
| Average volume | 128.35K | 437.31K |
| Shares outstanding | 43.89M | 62.90M |
| Employees | 27 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alpha Teknova is about 3.3 times larger than Anbio Biotechnology by market value ($479.95M vs $145.72M).
- TKNO has outperformed NNNN by 163.5 percentage points over the past year.
- Anbio Biotechnology is more profitable, keeping 74.1 cents of every revenue dollar as net income versus -42.6 cents for Alpha Teknova.
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
NNNN vs TKNO FAQ
Which is bigger, Anbio Biotechnology or Alpha Teknova?
Alpha Teknova (TKNO) is larger, with a market capitalization of $479.95M compared with $145.72M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, NNNN or TKNO?
TKNO returned +77.44% over the past 12 months, compared with -86.02% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Anbio Biotechnology and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.